Published in Mol Ther on October 01, 2005
HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Med (2009) 2.56
Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol Ther (2008) 1.61
Reduced expression of brain-enriched microRNAs in glioblastomas permits targeted regulation of a cell death gene. PLoS One (2011) 1.34
Gene therapy for cancer treatment: past, present and future. Clin Med Res (2006) 1.30
Variable deficiencies in the interferon response enhance susceptibility to vesicular stomatitis virus oncolytic actions in glioblastoma cells but not in normal human glial cells. J Virol (2006) 1.24
The art of gene therapy for glioma: a review of the challenging road to the bedside. J Neurol Neurosurg Psychiatry (2012) 1.24
Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res (2009) 1.22
Toward brain tumor gene therapy using multipotent mesenchymal stromal cell vectors. Mol Ther (2010) 1.18
Prodrug approaches for CNS delivery. AAPS J (2008) 1.17
Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted? Br J Cancer (2013) 1.16
Viral strategies for studying the brain, including a replication-restricted self-amplifying delta-G vesicular stomatis virus that rapidly expresses transgenes in brain and can generate a multicolor golgi-like expression. J Comp Neurol (2009) 1.09
Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model. Cancer Gene Ther (2012) 1.08
Pseudotyping vesicular stomatitis virus with lymphocytic choriomeningitis virus glycoproteins enhances infectivity for glioma cells and minimizes neurotropism. J Virol (2011) 1.06
Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits. Mol Ther (2008) 1.05
Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety. Curr Gene Ther (2009) 1.04
Novel delivery strategies for glioblastoma. Cancer J (2012) 1.01
Restoration of tissue factor pathway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosis. Clin Cancer Res (2007) 0.98
Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma. Clin Pharmacol Ther (2010) 0.98
Polymeric nanoparticles for nonviral gene therapy extend brain tumor survival in vivo. ACS Nano (2015) 0.96
Turning the gene tap off; implications of regulating gene expression for cancer therapeutics. Mol Cancer Ther (2008) 0.94
Combination of taxol and Bcl-2 siRNA induces apoptosis in human glioblastoma cells and inhibits invasion, angiogenesis and tumour growth. J Cell Mol Med (2009) 0.94
High mobility group box2 promoter-controlled suicide gene expression enables targeted glioblastoma treatment. Mol Ther (2009) 0.93
High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity. J Virol (2008) 0.92
Novel membrane-permeable contrast agent for brain tumor detection by MRI. Magn Reson Med (2010) 0.92
Therapeutic nanomedicine for brain cancer. Ther Deliv (2013) 0.92
Current status of gene therapy for brain tumors. Transl Res (2012) 0.90
Knockdown of eukaryotic translation initiation factors 3B (EIF3B) inhibits proliferation and promotes apoptosis in glioblastoma cells. Neurol Sci (2012) 0.88
Gene therapy trials for the treatment of high-grade gliomas. Gene Ther Mol Biol (2007) 0.88
Combination of hTERT knockdown and IFN-gamma treatment inhibited angiogenesis and tumor progression in glioblastoma. Clin Cancer Res (2009) 0.87
Mesenchymal stem cell-mediated cancer therapy: A dual-targeted strategy of personalized medicine. World J Stem Cells (2011) 0.86
Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model. Neurotherapeutics (2012) 0.85
Clinically applicable human adipose tissue-derived mesenchymal stem cells delivering therapeutic genes to brainstem gliomas. Cancer Gene Ther (2015) 0.84
CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma. Cancer Gene Ther (2009) 0.84
Immune-mediated loss of transgene expression from virally transduced brain cells is irreversible, mediated by IFNγ, perforin, and TNFα, and due to the elimination of transduced cells. Mol Ther (2012) 0.84
Genetic analysis of intracranial tumors in a murine model of glioma demonstrate a shift in gene expression in response to host immunity. J Neuroimmunol (2006) 0.83
Suicide gene approach using a dual-expression lentiviral vector to enhance the safety of ex vivo gene therapy for bone repair. Gene Ther (2013) 0.82
Gene delivery to the nervous system. Mol Ther (2008) 0.81
Gene delivery into malignant glioma by infectivity-enhanced adenovirus: in vivo versus in vitro models. Neuro Oncol (2007) 0.80
Bovine herpesvirus 4 based vector as a potential oncolytic-virus for treatment of glioma. Virol J (2010) 0.80
Truncating the i-leader open reading frame enhances release of human adenovirus type 5 in glioma cells. Virol J (2011) 0.78
Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with Prodrugs. Mol Ther Nucleic Acids (2013) 0.78
A systematic review and meta-analysis of gene therapy in animal models of cerebral glioma: why did promise not translate to human therapy? Evid Based Preclin Med (2015) 0.78
Engineered Mesenchymal Stem Cells as an Anti-Cancer Trojan Horse. Stem Cells Dev (2016) 0.78
Specific inhibition of SRC kinase impairs malignant glioma growth in vitro and in vivo. Mol Ther Nucleic Acids (2012) 0.77
Choindroitinase ABC I-mediated enhancement of oncolytic virus spread and anti tumor efficacy: a mathematical model. PLoS One (2014) 0.77
Ovarian cancer gene therapy using HPV-16 pseudovirion carrying the HSV-tk gene. PLoS One (2012) 0.77
Improved Adeno-associated Viral Gene Transfer to Murine Glioma. J Genet Syndr Gene Ther (2013) 0.77
Effective small interfering RNA delivery in vitro via a new stearylated cationic peptide. Int J Nanomedicine (2015) 0.76
Enhancing Intracranial Delivery of Clinically Relevant Non-viral Gene Vectors. RSC Adv (2016) 0.75
Stem cell based gene therapy in prostate cancer. Biomed Res Int (2014) 0.75
Use of genetically engineered stem cells for glioma therapy. Oncol Lett (2015) 0.75
Clinical development of experimental therapies for malignant glioma. Sultan Qaboos Univ Med J (2011) 0.75
Anti-Epidermal Growth Factor Receptor Gene Therapy for Glioblastoma. PLoS One (2016) 0.75
Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine. Genes Dis (2017) 0.75
Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst (2002) 3.44
VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology (2008) 2.53
Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res (2005) 2.48
VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci U S A (2009) 1.91
Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood (2005) 1.71
Angiogenesis-dependent and independent phases of intimal hyperplasia. Circulation (2004) 1.71
Enhanced capillary formation stimulated by a chimeric vascular endothelial growth factor/vascular endothelial growth factor-C silk domain fusion protein. Circ Res (2007) 1.48
Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor. FASEB J (2003) 1.38
Vascular endothelial growth factor-C accelerates diabetic wound healing. Am J Pathol (2006) 1.30
HIF-1 induction attenuates Nrf2-dependent IL-8 expression in human endothelial cells. Antioxid Redox Signal (2009) 1.09
Adenovirus-mediated extracellular superoxide dismutase gene therapy reduces neointima formation in balloon-denuded rabbit aorta. Circulation (2002) 1.00
Vascular endothelial growth factor-A induces plaque expansion in ApoE knock-out mice by promoting de novo leukocyte recruitment. Blood (2006) 0.99
Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice. Mol Ther (2008) 0.98
Molecular genetics of atherosclerosis. Hum Genet (2009) 0.95
Vascular endothelial growth factor-C gene therapy restores lymphatic flow across incision wounds. FASEB J (2004) 0.94
Combined vascular endothelial growth factor-A and fibroblast growth factor 4 gene transfer improves wound healing in diabetic mice. Genet Vaccines Ther (2010) 0.92
Human gene therapy and imaging: cardiology. Eur J Nucl Med Mol Imaging (2005) 0.88
Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma. Int J Cancer (2012) 0.88
Endothelial 15-lipoxygenase-1 overexpression increases acetylcholine-induced hypotension and vasorelaxation in rabbits. Hypertension (2008) 0.88
A highly reproducible xenograft model for human ovarian carcinoma and application of MRI and ultrasound in longitudinal follow-up. Gynecol Oncol (2006) 0.88
The combination of HSV-tk and endostatin gene therapy eradicates orthotopic human renal cell carcinomas in nude mice. Cancer Gene Ther (2002) 0.84
Apolipoprotein E and colon cancer. Expression in normal and malignant human intestine and effect on cultured human colonic adenocarcinoma cells. Eur J Intern Med (2002) 0.84
Adenoviral expression of 15-lipoxygenase-1 in rabbit aortic endothelium: role in arachidonic acid-induced relaxation. Am J Physiol Heart Circ Physiol (2006) 0.84
A preclinical assessment of the safety and biodistribution of an adenoviral vector containing the herpes simplex virus thymidine kinase gene (Cerepro) after intracerebral administration. J Gene Med (2009) 0.81
Effect of adventitial VEGF(165) gene transfer on vascular thickening after coronary artery balloon injury. Cardiovasc Res (2003) 0.79
Gene therapy in age related macular degeneration and hereditary macular disorders. Front Biosci (Elite Ed) (2012) 0.78
A stable bis-allyloxycarbonyl biotin aldehyde derivative for biotinylation via reductive alkylation: application to the synthesis of a biotinylated doxorubicin derivative. Bioconjug Chem (2003) 0.78
Adventitial gene transfer of VEGFR-2 specific VEGF-E chimera induces MCP-1 expression in vascular smooth muscle cells and enhances neointimal formation. Atherosclerosis (2011) 0.77
Tissue inhibitor of metalloproteinase 1 adenoviral gene therapy alone is equally effective in reducing restenosis as combination gene therapy in a rabbit restenosis model. J Vasc Res (2005) 0.77
Vascular oligonucleotide transfer facilitated by a polymer-coated stent. Hum Gene Ther (2005) 0.77
Computed tomographic coronary angiography for patients with heart failure (CTA-HF): a randomized controlled trial (IMAGE HF Project 1-C). Trials (2013) 0.75
Call for papers: Nanoparticle Development and Applications in Cellular and Molecular Therapies. Mol Ther (2016) 0.75
Cerivastatin and hypercholesterolemia reduce apoptosis of cardiomyocytes in guinea pig papillary muscle subjected to hypoxia/reoxygenation. Pharmacol Rep (2006) 0.75
Experimental hyperlipidaemia does not prevent preconditioning and it reduces ischemia-induced apoptosis. Int J Cardiol (2007) 0.75